Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer

Abstract

To evaluate objective response rates (ORR), progression-free survival (PFS), and overall survival (OS) associated with tyrosine kinase inhibitors (TKIs) in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC). Additionally, to compare: i) ORR and PFS among patients treated with lenvatinib and sorafenib; ii) ORR and PFS among patients receiving lenvatinib as rst-line vs. second-line and; iii) adverse effects (AEs) observed in patients treated with these medications. MethodsRetrospective analysis of RR-DTC adult patients treated with TKIs at the Division of Endocrinology, University of Buenos Aires (March 2011-November 2023). ResultsAmong 43 patients included in the study, 32 received sorafenib (30 as rst-line and 2 as second-line), while 29 received lenvatinib (12 as rst-line and 17 as second-line). The median PFS and OS for the entire cohort were 32.7 and 39.0 months, respectively. Lenvatinib demonstrated a signi cantly higher ORR compared to sorafenib (37.9% vs. 9.4%, p = 0.008). However, both drugs exhibited similar median PFS (23.2 vs. 16.0 months, p = 0.419). No signi cant difference was observed in ORR and PFS between patients receiving rst-line vs. second-line lenvatinib. Sorafenib-treated patients experienced higher rates of hand-foot skin syndrome (69% vs. 41%, p = 0.032) and alopecia (25% vs. 3%, p = 0.018), whereas lenvatinib-treated patients had higher rates of proteinuria (31% vs. 0%, p < 0.001) and grade 3 hypertension (31% vs. 9%, p = 0.034). ConclusionTKIs demonstrated e cacy and tolerability comparable to real-world data in RR-DTC. PFS was not statistically different between sorafenib and lenvatinib. Our study will help guide physicians in making informed decisions regarding treatment sequencing with TKIs in these patients.